Background
Since the global outbreak in 2022, mpox has continued to circulate worldwide. Previous studies have demonstrated that mpox vaccination can prevent severe disease but have lacked adjustment for differences in age or health status between vaccinated and unvaccinated individuals. Our analysis aimed to compare disease severity among those who were vaccinated to those who were unvaccinated while adjusting for confounders. We also explored whether time since vaccination impacted mpox disease severity.
Methods
We conducted a retrospective analysis of all probable and confirmed cases of mpox reported in Washington from January 2023 to June 2025 using surveillance data enriched with medical records. We used an adapted version of the Mpox Severity Scoring System to assess mpox disease severity. An individual was considered vaccinated if they received at least one dose of the MVA-BN vaccine. We used linear regression adjusted for age and immunocompromising conditions to estimate the association between vaccination status and disease severity. Among those who were vaccinated, we used linear regression to quantify the relationship between time since last vaccine dose (<12 months, 12-<24 months, 24+ months) and disease severity.
Results
Of the 175 cases of mpox reported, 164 cases met our inclusion criteria. The majority (82%) identified as cis-gender men, while 7% identified as another gender identity. Ninety-four individuals were vaccinated (57%), and 70 individuals were unvaccinated (43%). The mean severity score of vaccinated individuals was 4.6 points (SD 1.7). Those who were vaccinated had a lower mpox severity score by 1.44 points (95% CI 0.79-2.09, p<0.001) compared to those who were unvaccinated. After adjusting for age and immunocompromising condition, vaccinated individuals had a lower severity score by 1.48 points (95% CI 0.77-2.19, p<0.001). Individuals vaccinated more than two years prior to infection had a greater severity score by 0.97 points (95% CI 0.07-1.87, p=0.035), compared to cases vaccinated within the prior year. After adjusting, the difference was 0.93 points (95% CI -0.12-1.98, p=0.082).
Conclusions
Our results suggest that mpox vaccination protects individuals from having more severe disease and that individuals who received their vaccine more than two years ago may be at risk of more severe disease than those more recently vaccinated. The impacts of waning immunity need to be studied further to ensure that communities receive appropriate therapeutics and interventions.